We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Advanced Prostate Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
52 y/o With High Volume Lung, Mediastinal, Bone, and Pelvic Nodes Metastatic Prostate Cancer With Primary Tumor of 9.5cm With Germ Line BARD1 and Somatic BRAFV463 Mutation
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Juan Artigas
Oct 02, 2021
Recent studies have shown an survival advantage when abiraterone plus docetaxel is used in the novo metastatic hormone sensitive PC. Adding docetaxel may be something to consider and discuss with the patient.
Eman Ahmed
Oct 08, 2021
I do opt for addition of SBRT to the primary tumor to the present treatment as long as there is marvellous response with disappearance of all mets and only small residual at primary site
Charles Maack
Oct 08, 2021
Add SBRT to primary tumor to present treatment. Question why Orgovix replaced Firmagon given that it is an oral medication and may not be covered by many insurers unless covered by Medicare Plan D. Also, not certain it is any more effective than Firmagon. Given that ADT has been effective to date, metastasis found to have disappeared, and lab results as desired, continue ADT, but target the tumor to hopefully clear this patient's PCa activity
Christos Galanopoulos
Oct 08, 2021
Orgavix changed from formalin due to physical symptoms/reaction at site of injection- patient states his overall performance status improved and side effects lessoned following the switch.
Charles Maack
Oct 08, 2021
Christos: Did patient have to pay for the Orgovyx (relugolix) ?
Christos Galanopoulos
Oct 08, 2021
Insurance covered with copay of $35
Christos Galanopoulos
Oct 08, 2021
And all labs stayed good- PSA dropped to 0.04 and T level still <10 x 3 months of use
Christos Galanopoulos
Oct 08, 2021
Would anyone get PSMA PET since initially high volume metastasis converted to low volume
Charles Maack
Oct 08, 2021
I am trying to make sure reinsurance coverage for this oral medication in order to advise patients if considering. Dear Christos: Thus, was this patient covered by, and was it, Medicare Part D? The importance to patients is, of course, since this is otherwise an extremely expensive medication. As to PSMA PET: if you mean as a 68 Ga-labeled, PSMA-targeted radiotracer, Ga 68 PSMA-11 used with PET/CT and PET/MRI with what is known as the patient's current status, it would appear unnecessary at this time.
Christos Galanopoulos
Oct 08, 2021
He has private employer supplied insurance- If planning Lu-177 then he will need a PSMA PET
Charles Maack
Oct 09, 2021
For Christos: Thank you for submitting this case for discussion and for your responses to my remarks. I have been a mentor online to men diagnosed and to their caregivers for over two decades. If interested, type Charles (Chuck) Maack in the internet search box and result will direct you to my website. I was hoping Dr. Sartor might comment here, so we shall see.
Charles Maack
Oct 09, 2021
I notice no one has yet commented regarding the presence of Germ Line BARD1 and Somatic BRAFV463 Mutation. Here, as well, based on the patients current status, it appears they are not having any effect on the patient's significant improvement with current ADT medications so, if anything, keeping aware and if things begin to go haywire, look further into this presence to determine if playing any role in the change of status.
Prasanta Kumar Pradhan
Apr 02, 2022
C.Add SBRT
Apr 16, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Juan Artigas
Oct 02, 2021
Eman Ahmed
Oct 08, 2021
Charles Maack
Oct 08, 2021
Christos Galanopoulos
Oct 08, 2021
Charles Maack
Oct 08, 2021
Christos Galanopoulos
Oct 08, 2021
Christos Galanopoulos
Oct 08, 2021
Christos Galanopoulos
Oct 08, 2021
Charles Maack
Oct 08, 2021
Christos Galanopoulos
Oct 08, 2021
Charles Maack
Oct 09, 2021
Charles Maack
Oct 09, 2021
Prasanta Kumar Pradhan
Apr 02, 2022
Apr 16, 2024
Pending Moderator approval.